MANHARD KIMBERLY 4
4 · Inhibrx Biosciences, Inc. · Filed May 30, 2024
Insider Transaction Report
Form 4
MANHARD KIMBERLY
Director
Transactions
- Award
Stock Option (right to buy)
2024-05-30+30,000→ 30,000 totalExercise: $15.86Exp: 2034-05-30→ Common Stock (30,000 underlying)
Footnotes (2)
- [F1]This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
- [F2]This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.